Mometasone cream-quinacrine naruzhn.prim-I 0.1% 15g tube 1 pc

Description

Composition
Active substance:
100 g of cream contains: mometasone furoate 0.1 g ;.
Excipients:
Hexylene glycol – 12.0 g, 40-55 glyceryl monostearate – 5.5 g cetostearyl alcohol – 5.5 g, tsetostearat macrogol (macrogol 20 cetostearyl ether) – 4.0 g white beeswax – 5.0 g of titanium dioxide – 1.0 g aluminum starch octenyl succinate – 10.0 g purified water – 1.8 g phosphoric acid, dilute or concentrated phosphoric acid as 10% solution – 1.2 g Vaseline – 100 g
Description:
Cream, white or nearly white.
Product form:
Cream for external use of 0.1%. At 15 and 30 g of aluminum into a tube. Each tube together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to any component of the formulation or to the gluco-corticosteroid agents.
Rosacea, perioral dermatitis.
Bacterial, viral (Herpes simplex, chickenpox, Herpes zoster), or a fungal infection of the skin.
Tuberculosis, syphilis.
Post-vaccination reactions.
Children up to age 6 months.
Pregnancy (treatment of large areas of skin, long-term treatment).
Lactation (used in large doses and / or for a long time).
Carefully. Applying to the skin of the face and in the folds, the use of occlusive dressings, as well as the treatment of large areas of skin and / or long-term treatment (particularly in children).
Dosage
0.1%
Indications
Inflammation and itching at dermatoses, measurable glucocorticosteroid therapy.
Overdose
Symptoms: inhibition of the function of the hypothalamic-pituitary-adrenal system,
including secondary adrenal insufficiency. Treatment: symptomatic, if necessary – correction of electrolyte imbalance,
removal of the drug (for long-term therapy – the phasing out).
pharmachologic effect
Pharmacological group:
Glucocorticosteroids for local use.
Pharmacodynamics:
Mometasone – synthetic glucocorticosteroid (GCS)
having anti-inflammatory, antipruritic and antiexudative action. GCS induce isolation of proteins that inhibit phospholipase A2 and known subtotal called lipocortin, which control the biosynthesis mediatorovvospaleniya such as prostaglandins and leukotrienes by inhibiting the release ihobschego precursor arachidonic acid.
Pharmacokinetics:
The absorption of Mometasone cream-Akrikhin insignificant. After 8 chasovposle application to intact skin (without occlusive dressings) sistemnomkrovotoke detected in about 0.4% of the formulation.
Pregnancy and breast-feeding
Safety of application of mometasone cream-Akrikhin ilaktatsii during pregnancy has not been studied. Glucocorticosteroids cross the placental barrier. Avoid long-term treatment and the use of large doses during pregnancy due to the risk of negative impact on fetal development. Glucocorticosteroids are excreted in breast milk. In the case where it is assumed the use of corticosteroids at high doses and / or for a long time, discontinue breastfeeding.
Conditions of supply of pharmacies
By prescription.
side effects
Rarely – skin irritation and dryness, burning sensation, pruritus, folliculitis, hypertrichosis,
acne, hypopigmentation, perioral dermatitis, allergic kontaktnyydermatit, skin maceration, accession secondary infection, symptoms atrofiikozhi, striae, sudamen. Less than 1% of the cases – the formation of papules, pustules. When applying a cream-furoate Akrikhin for a long time and / or large areas of skin dlyalecheniya or using occlusive dressings osobennou children and teenagers, can have side effects that are characteristic for corticosteroids
systemic effects, including adrenal insufficiency and Cushing’s syndrome.
special instructions
When applied to large areas of the skin for a long time, especially priprimenenii occlusive dressings may develop systemic corticosteroids. In view of this, patients should be observed for signs of suppression funktsiigipotalamo-pituitary-adrenal system and the development of Cushing’s syndrome. Avoid getting the cream mometasone-Akrikhin eyes. Propylene glycol, which is part of the preparation, may cause irritation mestenaneseniya. In such cases, discontinue use of mometasone-Akrikhin inaznachit appropriate treatment. Note that corticosteroids can change the display of some zabolevaniykozhi that can complicate diagnosis. In addition, use of corticosteroids mozhetbyt cause delays wound healing. When long-term therapy of GCS sudden cessation of therapy may result in rebound krazvitiyu syndrome, which manifests itself in the form of dermatitis skin intensivnympokrasneniem and burning sensation. Therefore, after the long course of the preparation should be carried lecheniyaotmenu gradually, for example, moving naintermittiruyuschuyu regimen before it is completely stopped.
Pediatric use
The safety and efficacy of a cream-furoate Akrikhin topically primeneniiu children during the period of more than 6 weeks, were not studied. Due to the fact that in children the value of the ratio of surface area and mass telabolshe than adults, children are at greater risk of suppression funktsiigipotalamo-pituitary-adrenal system and the development of Cushing’s syndrome priprimenenii any topical corticosteroids. Long-term treatment of children corticosteroids may impair their growth and development. Children should receive the minimum dose sufficient to achieve the effect. Children from 6 months to 2 years of treatment should not exceed 5 days.
Storage conditions
At a temperature of 15 to 25 C. Keep out of reach of children.
Dosing and Administration
Outwardly. A thin layer of cream-furoate Akrikhin applied to affected areas once daily kozhiodin. The duration of treatment is determined by its efficiency,
and tolerated by the patient, presence and severity of side effects.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist